Opendata, web and dolomites

PNEUMOSIP SIGNED

PNEUMOSIP

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PNEUMOSIP project word cloud

Explore the words cloud of the PNEUMOSIP project. It provides you a very rough idea of what is the project "PNEUMOSIP" about.

relationship    bacteria    resistances    empiric    disease    laboratory    pneumonia    diseases    first    appropriate    automated    discarded    rapid    child    hib    elderly    streptococcus    population    combine    accurate    clinicians    patient    antibiotic    mainstream    acts    children    poct    community    haemophilus    precision    million    tests    time    slowness    causal    treatment    useless    populations    market    cap    identification    acquired    concretely    influenzae    diagnostic    hospital    agents    faster    poc    pneumosip    detection    host    analysing    death    pathogens    infected    compact    pneumoniae    fast    415    therapy    device    administration    aetiological    simplicity    rsv    syncytial    virus    starting    hours       healthy    responsible    70    world    arrival    diagnosing    2012    quantitative    nasopharynx    antibiotics    valued    fourth    guidelines    standard    colonizer    respiratory    segment    aetiology    infectious    diagnose    adult    treatments    complication   

Project "PNEUMOSIP" data sheet

The following table provides information about the project.

Coordinator
LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP 

Organization address
address: CALLE CERVANTES 40 - 3P - PC
city: ZARAGOZA
postcode: 50006
website: www.alphasip.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.pneumosipdx.com
 Total cost 3˙389˙912 €
 EC max contribution 3˙389˙912 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LABORATORIOS ALPHA SAN IGNACIO PHARMA S.L. - ALPHASIP ES (ZARAGOZA) coordinator 3˙389˙912.00

Map

 Project objective

PneumoSIP project aims to be the first fully automated device in the POC market for the fast quantitative aetiological diagnose of Community-Acquired Pneumonia (CAP) also analysing antibiotic resistances to enable the most appropriate treatment for each infected patient. CAP is known to affect about 1/1,000 of the adult population per year, being even higher in the elderly and children populations. It is the fourth case of death in the world, and the leading cause of death in child population under 5 years old. The causal relationship between pathogens and pneumonia has been clearly established, being Streptococcus pneumoniae, Haemophilus influenzae type b (Hib) and the respiratory syncytial virus (RSV) the main pathogens responsible for CAP in Europe. Antibiotic therapy is the mainstream treatment for CAP, and the appropriate treatment involves starting empiric antibiotics administration within 8 hours of hospital arrival. Given this time constrain, traditional methods for diagnosing the aetiology of CAP have been discarded for CAP guidelines due to the slowness in sample to results. Another complication is that S. pneumoniae is a common colonizer of the nasopharynx (up to 70% of healthy population acts as a host), making the simple detection of the bacteria a useless diagnostic method. Thus, clinicians need rapid and accurate quantitative tests capable of identifying infectious agents and their potential antibiotic resistances. Therefore, PneumoSIP project aims to be a compact Respiratory Infectious Diseases diagnostic device providing fast quantitative identification of pathogens involved in CAP, enabling faster and more specific treatments. PneumoSIP seeks to combine laboratory standard precision with the simplicity required for POC applications. The market for PneumoSIP system is the POC market, concretely the Infectious Disease POC testing segment. The POCT segment was valued at $415.4 million in 2012 where Pneumosip will greatly impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PNEUMOSIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PNEUMOSIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

PNEUMOSIP (2015)

PNEUMOSIP

Read More  

OncoMasTR (2016)

OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer

Read More  

Respiratory-ImmunoDx (2015)

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Read More